新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 英国科学家发现心房颤动并发症生物标记物

英国科学家发现心房颤动并发症生物标记物

来源:生物谷 2013-11-13 21:34

2013年11月13日讯 /生物谷BIOON/ --患有心房颤动症的患者通常也会伴随一些并发症。最近英国的科学家研究出一种生物标记物能够帮助鉴定患者是否会患有这种并发症。来自英国伯明翰大学的研究人员调查了1279名心房颤动的患者后发现,如果患者体内一种BTP蛋白含量越高,其患心房颤动并发症的可能越大,严重时甚至会导致死亡。BTP目前已经被用来作为一些肾脏疾病和炎症的生物标记物。(生物谷Bioon.com)

详细英文报道:

Patients with atrial fibrillation, a common cardiac arrhythmia, are often at a heightened risk for stroke and other health problems. But researchers in the U.K. and elsewhere believe they have identified a biomarker that can help screen for folks who face a greater likelihood of complications.

Scientists at the University of Birmingham in the U.K. and colleagues pursued the research, and the journal CHEST details their work. MedPage Today highlights the findings.

The research team studied 1,279 elderly atrial fibrillation patients treated with an oral drug to prevent blood clots, according to the story. With this class of patients, they found that high levels of beta-trace protein, or BTP, could be linked to larger risks of everything from "embolic events" to cardiac problems, bleeding and death. Additionally, they surmised that BTP levels added to other risk scores helped improve the process of identifying potential health complications in atrial fibrillation patients.

Interestingly, BTP has already been in play as a possible biomarker, but for factors such as kidney damage, inflammation and hypertension, the MedPage Today article pointed out.

These are promising early results, but the data include plenty of limitations. As the article notes, the researchers themselves acknowledge that their work only looked at patients on a regular oral anticlotting drug at a certain point in time. Further research must include a broader class of patients to determine if BTP can be a reliable biomarker to help identify atrial fibrillation patients with an added risk of other health problems.

As hard as it might be to spot atrial fibrillation patients at risk of more problems, doctors struggle to definitively identify the condition in the first place and apply targeted treatments. The med tech industry, meanwhile, is trying to fill the gap. Topera, a 2013 Fierce 15 winner, recently won U.S. and EU approval for a 3-D device and mapping tool designed to better detect cardiac rhythm problems such as atrial fibrillation in order to enable more targeted and accurate treatment. In late August, St. Jude Medical ($STJ) snatched up Endosense, which makes a cutting-edge irrigated ablation catheter designed to treat atrial fibrillation, and rival companies are developing or promoting electrophysiology treatments and other devices for the condition.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库